Are you over 18 and want to see adult content?
More Annotations
![A complete backup of www.hindustantimes.com/education/rsmssb-je-recruitment-2020-1054-vacancies-for-engineers-notified/story-Okd](https://www.archivebay.com/archive2/e39d7485-f8f3-4588-bc1d-60c3267523aa.png)
A complete backup of www.hindustantimes.com/education/rsmssb-je-recruitment-2020-1054-vacancies-for-engineers-notified/story-Okd
Are you over 18 and want to see adult content?
![A complete backup of www.superhaber.tv/mucize-doktor-22-bolum-izle-mucize-doktor-son-bolum-izle-fox-tv-canli-yayin-mucize-doktor](https://www.archivebay.com/archive2/de2ca8f4-6219-4aaa-95d5-441955e29d5b.png)
A complete backup of www.superhaber.tv/mucize-doktor-22-bolum-izle-mucize-doktor-son-bolum-izle-fox-tv-canli-yayin-mucize-doktor
Are you over 18 and want to see adult content?
![A complete backup of www.welt.de/kultur/pop/article205858829/No-time-to-die-Billie-Eilishs-Bond-Song-ist-grossartig-aber-kein-Bi](https://www.archivebay.com/archive2/1ef4a78d-8913-4341-a0b2-c7543a0dd4b7.png)
A complete backup of www.welt.de/kultur/pop/article205858829/No-time-to-die-Billie-Eilishs-Bond-Song-ist-grossartig-aber-kein-Bi
Are you over 18 and want to see adult content?
![A complete backup of www.tuttosport.com/news/calcio/calcio-estero/ligue-1/2020/02/13-66696619/psg_ansia_per_neymar_e_mbappe_uno_](https://www.archivebay.com/archive2/3ab1577e-f92d-4955-8f37-30faf08b2d57.png)
A complete backup of www.tuttosport.com/news/calcio/calcio-estero/ligue-1/2020/02/13-66696619/psg_ansia_per_neymar_e_mbappe_uno_
Are you over 18 and want to see adult content?
![A complete backup of www.firstpost.com/entertainment/world-famous-lover-movie-review-aishwarya-rajesh-steals-the-show-but-this-v](https://www.archivebay.com/archive2/6c22788a-cb88-47f6-a468-feeb60ca2913.png)
A complete backup of www.firstpost.com/entertainment/world-famous-lover-movie-review-aishwarya-rajesh-steals-the-show-but-this-v
Are you over 18 and want to see adult content?
Favourite Annotations
![A complete backup of https://joesecurity.org](https://www.archivebay.com/archive6/images/4f8a9ac5-20d2-48cb-a5dd-b34680f76bff.png)
A complete backup of https://joesecurity.org
Are you over 18 and want to see adult content?
![A complete backup of https://linhoff.at](https://www.archivebay.com/archive6/images/8fb111b8-e095-4e78-b31a-e80d3c3d6654.png)
A complete backup of https://linhoff.at
Are you over 18 and want to see adult content?
![A complete backup of https://blazinghotcasino.com](https://www.archivebay.com/archive6/images/36832e7e-a02d-46af-83a4-602c644d8d12.png)
A complete backup of https://blazinghotcasino.com
Are you over 18 and want to see adult content?
![A complete backup of https://teejunction.com.au](https://www.archivebay.com/archive6/images/6560559f-0628-4114-88e9-4a512ab72f00.png)
A complete backup of https://teejunction.com.au
Are you over 18 and want to see adult content?
![A complete backup of https://utapao.com](https://www.archivebay.com/archive6/images/e8ba8267-c4e8-4453-b89f-9f67b5111fe5.png)
A complete backup of https://utapao.com
Are you over 18 and want to see adult content?
![A complete backup of https://jawapos.co.id](https://www.archivebay.com/archive6/images/5efa6cfa-8f9f-4e70-9ca6-b2c43afc40f3.png)
A complete backup of https://jawapos.co.id
Are you over 18 and want to see adult content?
![A complete backup of https://boomsual.com](https://www.archivebay.com/archive6/images/7bcd59b2-6135-4a6b-90fd-9c7d383622de.png)
A complete backup of https://boomsual.com
Are you over 18 and want to see adult content?
![A complete backup of https://cptv.org](https://www.archivebay.com/archive6/images/328ecaaf-f81a-4aae-955d-e6e499136868.png)
A complete backup of https://cptv.org
Are you over 18 and want to see adult content?
![A complete backup of https://portstoronto.com](https://www.archivebay.com/archive6/images/394c9622-63de-4c45-b160-ceeaf00191ff.png)
A complete backup of https://portstoronto.com
Are you over 18 and want to see adult content?
![A complete backup of https://pixelflower.ch](https://www.archivebay.com/archive6/images/9dacb99d-7189-466f-91b5-d3412a54b60b.png)
A complete backup of https://pixelflower.ch
Are you over 18 and want to see adult content?
![A complete backup of https://diggsw.com](https://www.archivebay.com/archive6/images/4745074a-6097-4b2b-80c8-af5d60cc4560.png)
A complete backup of https://diggsw.com
Are you over 18 and want to see adult content?
![A complete backup of https://mamikos.com](https://www.archivebay.com/archive6/images/eb3377d4-80b7-4537-bec6-a00851b2b13b.png)
A complete backup of https://mamikos.com
Are you over 18 and want to see adult content?
Text
Hospital of UPMC,
PRELIMINARY SAFETY, EFFICACY, AND PHARMACOKINETIC Objective: TSR-042 is an investigational humanized antiprogrammed death (PD)–1 monoclonal antibody that binds with high affinity to the PD-1 receptor and effectively blocks interaction with the ligands PD-L1 and PD-L2. TSR-042 is being evaluated in patients with advanced solid tumors in the ongoing phase I/II GARNET trial (NCT02715284) (Sachdev JC et al. Ann Oncol. 2017(suppl SPERANZA PROJECT: HPV VACCINATION AFTER TREATMENT FOR CIN2 In 2006 HPV vaccination was licensed for primary prevention of HPV related disease in young females. . Only a few years after, immunological and clinical studies offered new perspectives with strong implications in HPV related diseases, opening to a new scenario: adult women vaccination . Subsequently, the quadrivalent HPV vaccine demonstrated efficacy against HPV infectionand
LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Objective: To determine if the combination of carboplatin and paclitaxel (TC) chemotherapy is clinically inferior to the combination of doxorubicin, cisplatin, and paclitaxel (TAP) chemotherapy with regard to survival. To assess differences in toxicity profile, specifically neurotoxicity and infection between TAP and TC. BLEOMYCIN, ETOPOSIDE, AND CISPLATIN COMBINATION THERAPY OF Bleomycin, Etoposide, and Cisplatin Combination Therapy of Ovarian Granulosa Cell Tumors and Other Stromal Malignancies: A Gynecologic Oncology Group Study1,2 Howard HORMONAL REPLACEMENT THERAPY IN PATIENTS AFTER CERVICAL GYNECOLOGIC ONCOLOGY 26, 169-177 (1987) Hormonal Replacement Therapy in Patients after Cervical Cancer Treatment ELZBIETA PLOCH, M.D. Department of Gynecological Oncology, Maria-Sktodowska Institute ofOncology in Warsaw,
PLATINUM DESENSITIZATION IN PATIENTS WITH CARBOPLATIN Following the CTCAE v. 4.03 we categorized grades 1 and 2 HSRs as mild/moderate and grades 3 and 4 as severe/life-threatening (Table 1). Finally, the number of successfully completed platinum cycles per- ARTICLES IN PRESS: GYNECOLOGIC ONCOLOGY Gynecologic oncology treatment modifications or delays in response to the COVID-19 pandemic in a publicly funded versus privately funded North American tertiary cancer center. Sabrina Piedimonte, Sue Li, Stephane Laframboise, Paulina Cybulska, Michael J. Worley Jr, Taymaa May. Published online: April 28, 2021. HORMONE THERAPY (HT) IN WOMEN WITH GYNECOLOGIC CANCERS AND6 Approximately 40% of women with gynecologic malignancies are pre- or perimenopausal at the time of diagnosis . Combined multimodality therapy including surgery, chemotherapy and/or radiation often results in induced menopause. The Society of Gynecologic Oncology and NCCN recommend prophylactic risk reducing surgery between ages 35–45, or at the completion of child GOG-99: ENDING THE CONTROVERSY REGARDING PELVIC At last, the results of Gynecological Oncology Group (GOG) trial 99, a randomized trial comparing postoperative pelvic radiotherapy (RT) to no additional treatment (NAT) in intermediate-risk endometrial carcinoma, are published by Keys et al. in this issue of Gynecologic Oncology. Ever since the first presentation of the results in 1998, the gynecologic oncology community has been eagerly LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Late-Breaking Abstracts Scientific Plenary III: Cutting Edge Science Sunday, March 25, 2012 Moderators: Tom Krivak, MD, Magee-WomensHospital of UPMC,
PRELIMINARY SAFETY, EFFICACY, AND PHARMACOKINETIC Objective: TSR-042 is an investigational humanized antiprogrammed death (PD)–1 monoclonal antibody that binds with high affinity to the PD-1 receptor and effectively blocks interaction with the ligands PD-L1 and PD-L2. TSR-042 is being evaluated in patients with advanced solid tumors in the ongoing phase I/II GARNET trial (NCT02715284) (Sachdev JC et al. Ann Oncol. 2017(suppl SPERANZA PROJECT: HPV VACCINATION AFTER TREATMENT FOR CIN2 In 2006 HPV vaccination was licensed for primary prevention of HPV related disease in young females. . Only a few years after, immunological and clinical studies offered new perspectives with strong implications in HPV related diseases, opening to a new scenario: adult women vaccination . Subsequently, the quadrivalent HPV vaccine demonstrated efficacy against HPV infectionand
LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Objective: To determine if the combination of carboplatin and paclitaxel (TC) chemotherapy is clinically inferior to the combination of doxorubicin, cisplatin, and paclitaxel (TAP) chemotherapy with regard to survival. To assess differences in toxicity profile, specifically neurotoxicity and infection between TAP and TC. BLEOMYCIN, ETOPOSIDE, AND CISPLATIN COMBINATION THERAPY OF Bleomycin, Etoposide, and Cisplatin Combination Therapy of Ovarian Granulosa Cell Tumors and Other Stromal Malignancies: A Gynecologic Oncology Group Study1,2 Howard HORMONAL REPLACEMENT THERAPY IN PATIENTS AFTER CERVICAL GYNECOLOGIC ONCOLOGY 26, 169-177 (1987) Hormonal Replacement Therapy in Patients after Cervical Cancer Treatment ELZBIETA PLOCH, M.D. Department of Gynecological Oncology, Maria-Sktodowska Institute ofOncology in Warsaw,
PLATINUM DESENSITIZATION IN PATIENTS WITH CARBOPLATIN Following the CTCAE v. 4.03 we categorized grades 1 and 2 HSRs as mild/moderate and grades 3 and 4 as severe/life-threatening (Table 1). Finally, the number of successfully completed platinum cycles per- ARTICLES IN PRESS: GYNECOLOGIC ONCOLOGY Gynecologic oncology treatment modifications or delays in response to the COVID-19 pandemic in a publicly funded versus privately funded North American tertiary cancer center. Sabrina Piedimonte, Sue Li, Stephane Laframboise, Paulina Cybulska, Michael J. Worley Jr, Taymaa May. Published online: April 28, 2021. 51ST ANNUAL MEETING OF THE SOCIETY The Society of Gynecologic Oncology (SGO) was scheduled to conduct its 2020 Annual Meeting on Women's Cancer®, March 28–31, in Toronto, Canada. Due to the COVID-19 global pandemic, SGO decided not to conduct its annual meeting for the first time in its history. On March 28, SGO released all annual meeting abstracts to the general public, and in April launched a series of free webinars to ENHANCED RECOVERY AFTER SURGERY (ERAS®) IN GYNECOLOGIC There has been widespread interest in the Enhanced Recovery After Surgery (ERAS®) guidelines in gynecologic oncology as evidenced by these articles being among the most downloaded from the Journal since February 2016 . Despite this, many clinical departments still grapple with how to initiate their ERAS® program, particularly as it relates to translating the guidelines SPERANZA PROJECT: HPV VACCINATION AFTER TREATMENT FOR CIN2 In 2006 HPV vaccination was licensed for primary prevention of HPV related disease in young females. . Only a few years after, immunological and clinical studies offered new perspectives with strong implications in HPV related diseases, opening to a new scenario: adult women vaccination . Subsequently, the quadrivalent HPV vaccine demonstrated efficacy against HPV infectionand
A PHASE II TRIAL OF PEMBROLIZUMAB IN COMBINATION WITH Method: This is an open-label phase II study (with a safety lead-in cohort of n = 5) of pembrolizumab 200 mg IV in combination with bevacizumab 15 mg/kg IV every 3 weeks and oral cyclophosphamide 50 mg every day until disease progression or unacceptable toxicity. Key eligibility included RECIST 1.1 measurable platinum-resistant recurrent ovarian cancer or patient declines AN OPEN-LABEL, PHASE II BASKET STUDY OF OLAPARIB AND Objective: Olaparib (Lynparza™) is a poly(ADP-ribose) polymerase inhibitor (PARPi) approved for the treatment and maintenance therapy of ovarian cancer (OC). Here, the objective was to assess the efficacy and safety of olaparib in combination with durvalumab (Imfinzi™), an antiprogrammed cell death ligand-1 (PD-L1) agent, in the platinum-sensitive relapsed (PSR) OC HORMONAL REPLACEMENT THERAPY IN PATIENTS AFTER CERVICAL GYNECOLOGIC ONCOLOGY 26, 169-177 (1987) Hormonal Replacement Therapy in Patients after Cervical Cancer Treatment ELZBIETA PLOCH, M.D. Department of Gynecological Oncology, Maria-Sktodowska Institute ofOncology in Warsaw,
BLEOMYCIN, ETOPOSIDE, AND CISPLATIN COMBINATION THERAPY OF Bleomycin, Etoposide, and Cisplatin Combination Therapy of Ovarian Granulosa Cell Tumors and Other Stromal Malignancies: A Gynecologic Oncology Group Study1,2 Howard CURRENT STATUS OF THERAPEUTIC HPV VACCINES Invited Review Current status of therapeutic HPV vaccines Katharine T. Clark, Cornelia L. Trimble⁎ Department of Gynecology and Obstetrics, Johns Hopkins University, School of PHASE II TRIAL OF VINORELBINE FOR RELAPSED OVARIAN CANCER Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study Mace L. Rothenberga,*, P.Y. Liub, Sharon Wilczynskic, William A. Nahhasd HOME PAGE: GYNECOLOGIC ONCOLOGYHOMEPODCASTSSUBSCRIBEEDITORIAL BOARDCONTACT INFORMATIONABOUT THE JOURNAL The Society of Gynecologic Oncology (SGO) is the premier medical specialty society for health care professionals trained in the comprehensive management of gynecologic cancers. As a 501(c)(6) organization, the SGO contributes to the advancement of women's cancer care by encouraging research, providing education, raising standards of practice, advocating for patients and members and ARTICLES IN PRESS: GYNECOLOGIC ONCOLOGY Gynecologic oncology treatment modifications or delays in response to the COVID-19 pandemic in a publicly funded versus privately funded North American tertiary cancer center. Sabrina Piedimonte, Sue Li, Stephane Laframboise, Paulina Cybulska, Michael J. Worley Jr, Taymaa May. Published online: April 28, 2021. HORMONE THERAPY (HT) IN WOMEN WITH GYNECOLOGIC CANCERS AND Approximately 40% of women with gynecologic malignancies are pre- or perimenopausal at the time of diagnosis . Combined multimodality therapy including surgery, chemotherapy and/or radiation often results in induced menopause. The Society of Gynecologic Oncology and NCCN recommend prophylactic risk reducing surgery between ages 35–45, or at the completion of child GOG-99: ENDING THE CONTROVERSY REGARDING PELVIC At last, the results of Gynecological Oncology Group (GOG) trial 99, a randomized trial comparing postoperative pelvic radiotherapy (RT) to no additional treatment (NAT) in intermediate-risk endometrial carcinoma, are published by Keys et al. in this issue of Gynecologic Oncology. Ever since the first presentation of the results in 1998, the gynecologic oncology community has been eagerly LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Late-Breaking Abstracts Scientific Plenary III: Cutting Edge Science Sunday, March 25, 2012 Moderators: Tom Krivak, MD, Magee-WomensHospital of UPMC,
PRELIMINARY SAFETY, EFFICACY, AND PHARMACOKINETIC Objective: TSR-042 is an investigational humanized antiprogrammed death (PD)–1 monoclonal antibody that binds with high affinity to the PD-1 receptor and effectively blocks interaction with the ligands PD-L1 and PD-L2. TSR-042 is being evaluated in patients with advanced solid tumors in the ongoing phase I/II GARNET trial (NCT02715284) (Sachdev JC et al. Ann Oncol. 2017(suppl LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Objective: To determine if the combination of carboplatin and paclitaxel (TC) chemotherapy is clinically inferior to the combination of doxorubicin, cisplatin, and paclitaxel (TAP) chemotherapy with regard to survival. To assess differences in toxicity profile, specifically neurotoxicity and infection between TAP and TC. HORMONAL REPLACEMENT THERAPY IN PATIENTS AFTER CERVICAL GYNECOLOGIC ONCOLOGY 26, 169-177 (1987) Hormonal Replacement Therapy in Patients after Cervical Cancer Treatment ELZBIETA PLOCH, M.D. Department of Gynecological Oncology, Maria-Sktodowska Institute ofOncology in Warsaw,
AN OPEN-LABEL, PHASE II BASKET STUDY OF OLAPARIB AND Objective: Olaparib (Lynparza™) is a poly(ADP-ribose) polymerase inhibitor (PARPi) approved for the treatment and maintenance therapy of ovarian cancer (OC). Here, the objective was to assess the efficacy and safety of olaparib in combination with durvalumab (Imfinzi™), an antiprogrammed cell death ligand-1 (PD-L1) agent, in the platinum-sensitive relapsed (PSR) OC PLATINUM DESENSITIZATION IN PATIENTS WITH CARBOPLATIN Following the CTCAE v. 4.03 we categorized grades 1 and 2 HSRs as mild/moderate and grades 3 and 4 as severe/life-threatening (Table 1). Finally, the number of successfully completed platinum cycles per- HOME PAGE: GYNECOLOGIC ONCOLOGYHOMEPODCASTSSUBSCRIBEEDITORIAL BOARDCONTACT INFORMATIONABOUT THE JOURNAL The Society of Gynecologic Oncology (SGO) is the premier medical specialty society for health care professionals trained in the comprehensive management of gynecologic cancers. As a 501(c)(6) organization, the SGO contributes to the advancement of women's cancer care by encouraging research, providing education, raising standards of practice, advocating for patients and members and ARTICLES IN PRESS: GYNECOLOGIC ONCOLOGY Gynecologic oncology treatment modifications or delays in response to the COVID-19 pandemic in a publicly funded versus privately funded North American tertiary cancer center. Sabrina Piedimonte, Sue Li, Stephane Laframboise, Paulina Cybulska, Michael J. Worley Jr, Taymaa May. Published online: April 28, 2021. HORMONE THERAPY (HT) IN WOMEN WITH GYNECOLOGIC CANCERS AND Approximately 40% of women with gynecologic malignancies are pre- or perimenopausal at the time of diagnosis . Combined multimodality therapy including surgery, chemotherapy and/or radiation often results in induced menopause. The Society of Gynecologic Oncology and NCCN recommend prophylactic risk reducing surgery between ages 35–45, or at the completion of child GOG-99: ENDING THE CONTROVERSY REGARDING PELVIC At last, the results of Gynecological Oncology Group (GOG) trial 99, a randomized trial comparing postoperative pelvic radiotherapy (RT) to no additional treatment (NAT) in intermediate-risk endometrial carcinoma, are published by Keys et al. in this issue of Gynecologic Oncology. Ever since the first presentation of the results in 1998, the gynecologic oncology community has been eagerly LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Late-Breaking Abstracts Scientific Plenary III: Cutting Edge Science Sunday, March 25, 2012 Moderators: Tom Krivak, MD, Magee-WomensHospital of UPMC,
PRELIMINARY SAFETY, EFFICACY, AND PHARMACOKINETIC Objective: TSR-042 is an investigational humanized antiprogrammed death (PD)–1 monoclonal antibody that binds with high affinity to the PD-1 receptor and effectively blocks interaction with the ligands PD-L1 and PD-L2. TSR-042 is being evaluated in patients with advanced solid tumors in the ongoing phase I/II GARNET trial (NCT02715284) (Sachdev JC et al. Ann Oncol. 2017(suppl LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Objective: To determine if the combination of carboplatin and paclitaxel (TC) chemotherapy is clinically inferior to the combination of doxorubicin, cisplatin, and paclitaxel (TAP) chemotherapy with regard to survival. To assess differences in toxicity profile, specifically neurotoxicity and infection between TAP and TC. HORMONAL REPLACEMENT THERAPY IN PATIENTS AFTER CERVICAL GYNECOLOGIC ONCOLOGY 26, 169-177 (1987) Hormonal Replacement Therapy in Patients after Cervical Cancer Treatment ELZBIETA PLOCH, M.D. Department of Gynecological Oncology, Maria-Sktodowska Institute ofOncology in Warsaw,
AN OPEN-LABEL, PHASE II BASKET STUDY OF OLAPARIB AND Objective: Olaparib (Lynparza™) is a poly(ADP-ribose) polymerase inhibitor (PARPi) approved for the treatment and maintenance therapy of ovarian cancer (OC). Here, the objective was to assess the efficacy and safety of olaparib in combination with durvalumab (Imfinzi™), an antiprogrammed cell death ligand-1 (PD-L1) agent, in the platinum-sensitive relapsed (PSR) OC PLATINUM DESENSITIZATION IN PATIENTS WITH CARBOPLATIN Following the CTCAE v. 4.03 we categorized grades 1 and 2 HSRs as mild/moderate and grades 3 and 4 as severe/life-threatening (Table 1). Finally, the number of successfully completed platinum cycles per- HOME PAGE: GYNECOLOGIC ONCOLOGY The Society of Gynecologic Oncology (SGO) is the premier medical specialty society for health care professionals trained in the comprehensive management of gynecologic cancers. As a 501(c)(6) organization, the SGO contributes to the advancement of women's cancer care by encouraging research, providing education, raising standards of practice, advocating for patients and members and 51ST ANNUAL MEETING OF THE SOCIETY The Society of Gynecologic Oncology (SGO) was scheduled to conduct its 2020 Annual Meeting on Women's Cancer®, March 28–31, in Toronto, Canada. Due to the COVID-19 global pandemic, SGO decided not to conduct its annual meeting for the first time in its history. On March 28, SGO released all annual meeting abstracts to the general public, and in April launched a series of free webinars to ENHANCED RECOVERY AFTER SURGERY (ERAS®) IN GYNECOLOGIC There has been widespread interest in the Enhanced Recovery After Surgery (ERAS®) guidelines in gynecologic oncology as evidenced by these articles being among the most downloaded from the Journal since February 2016 . Despite this, many clinical departments still grapple with how to initiate their ERAS® program, particularly as it relates to translating the guidelines AN OPEN-LABEL, PHASE II BASKET STUDY OF OLAPARIB AND Objective: Olaparib (Lynparza™) is a poly(ADP-ribose) polymerase inhibitor (PARPi) approved for the treatment and maintenance therapy of ovarian cancer (OC). Here, the objective was to assess the efficacy and safety of olaparib in combination with durvalumab (Imfinzi™), an antiprogrammed cell death ligand-1 (PD-L1) agent, in the platinum-sensitive relapsed (PSR) OC LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Objective: To determine if the combination of carboplatin and paclitaxel (TC) chemotherapy is clinically inferior to the combination of doxorubicin, cisplatin, and paclitaxel (TAP) chemotherapy with regard to survival. To assess differences in toxicity profile, specifically neurotoxicity and infection between TAP and TC. NEOADJUVANT CHEMOTHERAPY FOLLOWED BY POST-PARTUM Cervical cancer is the most common malignancy in pregnancy with an incidence of 1.2–10.6 per 10,000 pregnancies. We report a case of FIGO stage IIIB glassy cell carcinoma (GCC) of the cervix presenting during pregnancy. This is the first report of a successful outcome with this histologic type of cervical cancer presenting at an advanced stage during pregnancy. THE GORE-TEX SURGICAL MEMBRANE: EFFECTIVENESS AS A BARRIER GYNECOLOGIC ONCOLOGY 45, 290-293 (1992) The Gore-Tex Surgical Membrane: Effectiveness as a Barrier to Inhibit Postradical Pelvic Surgery Adhesions in a Porcine Model’ PLATINUM DESENSITIZATION IN PATIENTS WITH CARBOPLATIN Following the CTCAE v. 4.03 we categorized grades 1 and 2 HSRs as mild/moderate and grades 3 and 4 as severe/life-threatening (Table 1). Finally, the number of successfully completed platinum cycles per- A PHASE III TRIAL OF SURGERY WITH OR WITHOUT ADJUNCTIVE The primary outcome, recurrence-free interval (RFI), is defined as the time from study entry to clinical, histologic, or radiographic evidence of disease recurrence. RAPID DESENSITIZATION FOR HYPERSENSITIVITY REACTIONS TO Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments Anna M. Feldwega, Chyh-Woei Leea, Ursula A. Matulonisb, Mariana Castellsa,* aDivision of Rheumatology, Immunology, and Allergy, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, 1 Jimmy Fund Way, ARTICLES IN PRESS: GYNECOLOGIC ONCOLOGY Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial HORMONE THERAPY (HT) IN WOMEN WITH GYNECOLOGIC CANCERS AND6 Approximately 40% of women with gynecologic malignancies are pre- or perimenopausal at the time of diagnosis . Combined multimodality therapy including surgery, chemotherapy and/or radiation often results in induced menopause. The Society of Gynecologic Oncology and NCCN recommend prophylactic risk reducing surgery between ages 35–45, or at the completion of child LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Late-Breaking Abstracts Scientific Plenary III: Cutting Edge Science Sunday, March 25, 2012 Moderators: Tom Krivak, MD, Magee-WomensHospital of UPMC,
GOG-99: ENDING THE CONTROVERSY REGARDING PELVIC At last, the results of Gynecological Oncology Group (GOG) trial 99, a randomized trial comparing postoperative pelvic radiotherapy (RT) to no additional treatment (NAT) in intermediate-risk endometrial carcinoma, are published by Keys et al. in this issue of Gynecologic Oncology. Ever since the first presentation of the results in 1998, the gynecologic oncology community has been eagerly LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Objective: To determine if the combination of carboplatin and paclitaxel (TC) chemotherapy is clinically inferior to the combination of doxorubicin, cisplatin, and paclitaxel (TAP) chemotherapy with regard to survival. To assess differences in toxicity profile, specifically neurotoxicity and infection between TAP and TC. SPERANZA PROJECT: HPV VACCINATION AFTER TREATMENT FOR CIN2 In 2006 HPV vaccination was licensed for primary prevention of HPV related disease in young females. . Only a few years after, immunological and clinical studies offered new perspectives with strong implications in HPV related diseases, opening to a new scenario: adult women vaccination . Subsequently, the quadrivalent HPV vaccine demonstrated efficacy against HPV infectionand
PRELIMINARY SAFETY, EFFICACY, AND PHARMACOKINETIC Objective: TSR-042 is an investigational humanized antiprogrammed death (PD)–1 monoclonal antibody that binds with high affinity to the PD-1 receptor and effectively blocks interaction with the ligands PD-L1 and PD-L2. TSR-042 is being evaluated in patients with advanced solid tumors in the ongoing phase I/II GARNET trial (NCT02715284) (Sachdev JC et al. Ann Oncol. 2017(suppl BLEOMYCIN, ETOPOSIDE, AND CISPLATIN COMBINATION THERAPY OF Bleomycin, Etoposide, and Cisplatin Combination Therapy of Ovarian Granulosa Cell Tumors and Other Stromal Malignancies: A Gynecologic Oncology Group Study1,2 Howard HORMONAL REPLACEMENT THERAPY IN PATIENTS AFTER CERVICAL GYNECOLOGIC ONCOLOGY 26, 169-177 (1987) Hormonal Replacement Therapy in Patients after Cervical Cancer Treatment ELZBIETA PLOCH, M.D. Department of Gynecological Oncology, Maria-Sktodowska Institute ofOncology in Warsaw,
PLATINUM DESENSITIZATION IN PATIENTS WITH CARBOPLATIN Following the CTCAE v. 4.03 we categorized grades 1 and 2 HSRs as mild/moderate and grades 3 and 4 as severe/life-threatening (Table 1). Finally, the number of successfully completed platinum cycles per- ARTICLES IN PRESS: GYNECOLOGIC ONCOLOGY Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial HORMONE THERAPY (HT) IN WOMEN WITH GYNECOLOGIC CANCERS AND6 Approximately 40% of women with gynecologic malignancies are pre- or perimenopausal at the time of diagnosis . Combined multimodality therapy including surgery, chemotherapy and/or radiation often results in induced menopause. The Society of Gynecologic Oncology and NCCN recommend prophylactic risk reducing surgery between ages 35–45, or at the completion of child LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Late-Breaking Abstracts Scientific Plenary III: Cutting Edge Science Sunday, March 25, 2012 Moderators: Tom Krivak, MD, Magee-WomensHospital of UPMC,
GOG-99: ENDING THE CONTROVERSY REGARDING PELVIC At last, the results of Gynecological Oncology Group (GOG) trial 99, a randomized trial comparing postoperative pelvic radiotherapy (RT) to no additional treatment (NAT) in intermediate-risk endometrial carcinoma, are published by Keys et al. in this issue of Gynecologic Oncology. Ever since the first presentation of the results in 1998, the gynecologic oncology community has been eagerly LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Objective: To determine if the combination of carboplatin and paclitaxel (TC) chemotherapy is clinically inferior to the combination of doxorubicin, cisplatin, and paclitaxel (TAP) chemotherapy with regard to survival. To assess differences in toxicity profile, specifically neurotoxicity and infection between TAP and TC. SPERANZA PROJECT: HPV VACCINATION AFTER TREATMENT FOR CIN2 In 2006 HPV vaccination was licensed for primary prevention of HPV related disease in young females. . Only a few years after, immunological and clinical studies offered new perspectives with strong implications in HPV related diseases, opening to a new scenario: adult women vaccination . Subsequently, the quadrivalent HPV vaccine demonstrated efficacy against HPV infectionand
PRELIMINARY SAFETY, EFFICACY, AND PHARMACOKINETIC Objective: TSR-042 is an investigational humanized antiprogrammed death (PD)–1 monoclonal antibody that binds with high affinity to the PD-1 receptor and effectively blocks interaction with the ligands PD-L1 and PD-L2. TSR-042 is being evaluated in patients with advanced solid tumors in the ongoing phase I/II GARNET trial (NCT02715284) (Sachdev JC et al. Ann Oncol. 2017(suppl BLEOMYCIN, ETOPOSIDE, AND CISPLATIN COMBINATION THERAPY OF Bleomycin, Etoposide, and Cisplatin Combination Therapy of Ovarian Granulosa Cell Tumors and Other Stromal Malignancies: A Gynecologic Oncology Group Study1,2 Howard HORMONAL REPLACEMENT THERAPY IN PATIENTS AFTER CERVICAL GYNECOLOGIC ONCOLOGY 26, 169-177 (1987) Hormonal Replacement Therapy in Patients after Cervical Cancer Treatment ELZBIETA PLOCH, M.D. Department of Gynecological Oncology, Maria-Sktodowska Institute ofOncology in Warsaw,
PLATINUM DESENSITIZATION IN PATIENTS WITH CARBOPLATIN Following the CTCAE v. 4.03 we categorized grades 1 and 2 HSRs as mild/moderate and grades 3 and 4 as severe/life-threatening (Table 1). Finally, the number of successfully completed platinum cycles per- HOME PAGE: GYNECOLOGIC ONCOLOGY The Society of Gynecologic Oncology (SGO) is the premier medical specialty society for health care professionals trained in the comprehensive management of gynecologic cancers. As a 501(c)(6) organization, the SGO contributes to the advancement of women's cancer care by encouraging research, providing education, raising standards of practice, advocating for patients and members and ARTICLES IN PRESS: GYNECOLOGIC ONCOLOGY Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial 51ST ANNUAL MEETING OF THE SOCIETY The Society of Gynecologic Oncology (SGO) was scheduled to conduct its 2020 Annual Meeting on Women's Cancer®, March 28–31, in Toronto, Canada. Due to the COVID-19 global pandemic, SGO decided not to conduct its annual meeting for the first time in its history. On March 28, SGO released all annual meeting abstracts to the general public, and in April launched a series of free webinars to SPERANZA PROJECT: HPV VACCINATION AFTER TREATMENT FOR CIN2 In 2006 HPV vaccination was licensed for primary prevention of HPV related disease in young females. . Only a few years after, immunological and clinical studies offered new perspectives with strong implications in HPV related diseases, opening to a new scenario: adult women vaccination . Subsequently, the quadrivalent HPV vaccine demonstrated efficacy against HPV infectionand
ENHANCED RECOVERY AFTER SURGERY (ERAS®) IN GYNECOLOGIC There has been widespread interest in the Enhanced Recovery After Surgery (ERAS®) guidelines in gynecologic oncology as evidenced by these articles being among the most downloaded from the Journal since February 2016 . Despite this, many clinical departments still grapple with how to initiate their ERAS® program, particularly as it relates to translating the guidelines BLEOMYCIN, ETOPOSIDE, AND CISPLATIN COMBINATION THERAPY OF Bleomycin, Etoposide, and Cisplatin Combination Therapy of Ovarian Granulosa Cell Tumors and Other Stromal Malignancies: A Gynecologic Oncology Group Study1,2 Howard A PHASE II TRIAL OF PEMBROLIZUMAB IN COMBINATION WITH Method: This is an open-label phase II study (with a safety lead-in cohort of n = 5) of pembrolizumab 200 mg IV in combination with bevacizumab 15 mg/kg IV every 3 weeks and oral cyclophosphamide 50 mg every day until disease progression or unacceptable toxicity. Key eligibility included RECIST 1.1 measurable platinum-resistant recurrent ovarian cancer or patient declines CURRENT STATUS OF THERAPEUTIC HPV VACCINES Invited Review Current status of therapeutic HPV vaccines Katharine T. Clark, Cornelia L. Trimble⁎ Department of Gynecology and Obstetrics, Johns Hopkins University, School of RAPID DESENSITIZATION FOR HYPERSENSITIVITY REACTIONS TO Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments Anna M. Feldwega, Chyh-Woei Leea, Ursula A. Matulonisb, Mariana Castellsa,* aDivision of Rheumatology, Immunology, and Allergy, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, 1 Jimmy Fund Way, WEEKLY TOPOTECAN FOR RECURRENT ENDOMETRIAL CANCER: A CASE Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature Tiffany A. Traina, Paul Sabbatini, Carol Aghajanian, Jakob Dupont* ARTICLES IN PRESS: GYNECOLOGIC ONCOLOGY Gynecologic oncology treatment modifications or delays in response to the COVID-19 pandemic in a publicly funded versus privately funded North American tertiary cancer center. Sabrina Piedimonte, Sue Li, Stephane Laframboise, Paulina Cybulska, Michael J. Worley Jr, Taymaa May. Published online: April 28, 2021. HORMONE THERAPY (HT) IN WOMEN WITH GYNECOLOGIC CANCERS AND6 Approximately 40% of women with gynecologic malignancies are pre- or perimenopausal at the time of diagnosis . Combined multimodality therapy including surgery, chemotherapy and/or radiation often results in induced menopause. The Society of Gynecologic Oncology and NCCN recommend prophylactic risk reducing surgery between ages 35–45, or at the completion of child GOG-99: ENDING THE CONTROVERSY REGARDING PELVIC At last, the results of Gynecological Oncology Group (GOG) trial 99, a randomized trial comparing postoperative pelvic radiotherapy (RT) to no additional treatment (NAT) in intermediate-risk endometrial carcinoma, are published by Keys et al. in this issue of Gynecologic Oncology. Ever since the first presentation of the results in 1998, the gynecologic oncology community has been eagerly LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Late-Breaking Abstracts Scientific Plenary III: Cutting Edge Science Sunday, March 25, 2012 Moderators: Tom Krivak, MD, Magee-WomensHospital of UPMC,
ENHANCED RECOVERY AFTER SURGERY (ERAS®) IN GYNECOLOGIC There has been widespread interest in the Enhanced Recovery After Surgery (ERAS®) guidelines in gynecologic oncology as evidenced by these articles being among the most downloaded from the Journal since February 2016 . Despite this, many clinical departments still grapple with how to initiate their ERAS® program, particularly as it relates to translating the guidelines PRELIMINARY SAFETY, EFFICACY, AND PHARMACOKINETIC Objective: TSR-042 is an investigational humanized antiprogrammed death (PD)–1 monoclonal antibody that binds with high affinity to the PD-1 receptor and effectively blocks interaction with the ligands PD-L1 and PD-L2. TSR-042 is being evaluated in patients with advanced solid tumors in the ongoing phase I/II GARNET trial (NCT02715284) (Sachdev JC et al. Ann Oncol. 2017(suppl LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Objective: To determine if the combination of carboplatin and paclitaxel (TC) chemotherapy is clinically inferior to the combination of doxorubicin, cisplatin, and paclitaxel (TAP) chemotherapy with regard to survival. To assess differences in toxicity profile, specifically neurotoxicity and infection between TAP and TC. BLEOMYCIN, ETOPOSIDE, AND CISPLATIN COMBINATION THERAPY OF Bleomycin, Etoposide, and Cisplatin Combination Therapy of Ovarian Granulosa Cell Tumors and Other Stromal Malignancies: A Gynecologic Oncology Group Study1,2 Howard HORMONAL REPLACEMENT THERAPY IN PATIENTS AFTER CERVICAL GYNECOLOGIC ONCOLOGY 26, 169-177 (1987) Hormonal Replacement Therapy in Patients after Cervical Cancer Treatment ELZBIETA PLOCH, M.D. Department of Gynecological Oncology, Maria-Sktodowska Institute ofOncology in Warsaw,
PLATINUM DESENSITIZATION IN PATIENTS WITH CARBOPLATIN Following the CTCAE v. 4.03 we categorized grades 1 and 2 HSRs as mild/moderate and grades 3 and 4 as severe/life-threatening (Table 1). Finally, the number of successfully completed platinum cycles per- ARTICLES IN PRESS: GYNECOLOGIC ONCOLOGY Gynecologic oncology treatment modifications or delays in response to the COVID-19 pandemic in a publicly funded versus privately funded North American tertiary cancer center. Sabrina Piedimonte, Sue Li, Stephane Laframboise, Paulina Cybulska, Michael J. Worley Jr, Taymaa May. Published online: April 28, 2021. HORMONE THERAPY (HT) IN WOMEN WITH GYNECOLOGIC CANCERS AND6 Approximately 40% of women with gynecologic malignancies are pre- or perimenopausal at the time of diagnosis . Combined multimodality therapy including surgery, chemotherapy and/or radiation often results in induced menopause. The Society of Gynecologic Oncology and NCCN recommend prophylactic risk reducing surgery between ages 35–45, or at the completion of child GOG-99: ENDING THE CONTROVERSY REGARDING PELVIC At last, the results of Gynecological Oncology Group (GOG) trial 99, a randomized trial comparing postoperative pelvic radiotherapy (RT) to no additional treatment (NAT) in intermediate-risk endometrial carcinoma, are published by Keys et al. in this issue of Gynecologic Oncology. Ever since the first presentation of the results in 1998, the gynecologic oncology community has been eagerly LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Late-Breaking Abstracts Scientific Plenary III: Cutting Edge Science Sunday, March 25, 2012 Moderators: Tom Krivak, MD, Magee-WomensHospital of UPMC,
ENHANCED RECOVERY AFTER SURGERY (ERAS®) IN GYNECOLOGIC There has been widespread interest in the Enhanced Recovery After Surgery (ERAS®) guidelines in gynecologic oncology as evidenced by these articles being among the most downloaded from the Journal since February 2016 . Despite this, many clinical departments still grapple with how to initiate their ERAS® program, particularly as it relates to translating the guidelines PRELIMINARY SAFETY, EFFICACY, AND PHARMACOKINETIC Objective: TSR-042 is an investigational humanized antiprogrammed death (PD)–1 monoclonal antibody that binds with high affinity to the PD-1 receptor and effectively blocks interaction with the ligands PD-L1 and PD-L2. TSR-042 is being evaluated in patients with advanced solid tumors in the ongoing phase I/II GARNET trial (NCT02715284) (Sachdev JC et al. Ann Oncol. 2017(suppl LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Objective: To determine if the combination of carboplatin and paclitaxel (TC) chemotherapy is clinically inferior to the combination of doxorubicin, cisplatin, and paclitaxel (TAP) chemotherapy with regard to survival. To assess differences in toxicity profile, specifically neurotoxicity and infection between TAP and TC. BLEOMYCIN, ETOPOSIDE, AND CISPLATIN COMBINATION THERAPY OF Bleomycin, Etoposide, and Cisplatin Combination Therapy of Ovarian Granulosa Cell Tumors and Other Stromal Malignancies: A Gynecologic Oncology Group Study1,2 Howard HORMONAL REPLACEMENT THERAPY IN PATIENTS AFTER CERVICAL GYNECOLOGIC ONCOLOGY 26, 169-177 (1987) Hormonal Replacement Therapy in Patients after Cervical Cancer Treatment ELZBIETA PLOCH, M.D. Department of Gynecological Oncology, Maria-Sktodowska Institute ofOncology in Warsaw,
PLATINUM DESENSITIZATION IN PATIENTS WITH CARBOPLATIN Following the CTCAE v. 4.03 we categorized grades 1 and 2 HSRs as mild/moderate and grades 3 and 4 as severe/life-threatening (Table 1). Finally, the number of successfully completed platinum cycles per- HOME PAGE: GYNECOLOGIC ONCOLOGY The Society of Gynecologic Oncology (SGO) is the premier medical specialty society for health care professionals trained in the comprehensive management of gynecologic cancers. As a 501(c)(6) organization, the SGO contributes to the advancement of women's cancer care by encouraging research, providing education, raising standards of practice, advocating for patients and members and ARTICLES IN PRESS: GYNECOLOGIC ONCOLOGY Gynecologic oncology treatment modifications or delays in response to the COVID-19 pandemic in a publicly funded versus privately funded North American tertiary cancer center. Sabrina Piedimonte, Sue Li, Stephane Laframboise, Paulina Cybulska, Michael J. Worley Jr, Taymaa May. Published online: April 28, 2021. 51ST ANNUAL MEETING OF THE SOCIETY The Society of Gynecologic Oncology (SGO) was scheduled to conduct its 2020 Annual Meeting on Women's Cancer®, March 28–31, in Toronto, Canada. Due to the COVID-19 global pandemic, SGO decided not to conduct its annual meeting for the first time in its history. On March 28, SGO released all annual meeting abstracts to the general public, and in April launched a series of free webinars to ENHANCED RECOVERY AFTER SURGERY (ERAS®) IN GYNECOLOGIC There has been widespread interest in the Enhanced Recovery After Surgery (ERAS®) guidelines in gynecologic oncology as evidenced by these articles being among the most downloaded from the Journal since February 2016 . Despite this, many clinical departments still grapple with how to initiate their ERAS® program, particularly as it relates to translating the guidelines BLEOMYCIN, ETOPOSIDE, AND CISPLATIN COMBINATION THERAPY OF Bleomycin, Etoposide, and Cisplatin Combination Therapy of Ovarian Granulosa Cell Tumors and Other Stromal Malignancies: A Gynecologic Oncology Group Study1,2 Howard A PHASE II TRIAL OF PEMBROLIZUMAB IN COMBINATION WITH Method: This is an open-label phase II study (with a safety lead-in cohort of n = 5) of pembrolizumab 200 mg IV in combination with bevacizumab 15 mg/kg IV every 3 weeks and oral cyclophosphamide 50 mg every day until disease progression or unacceptable toxicity. Key eligibility included RECIST 1.1 measurable platinum-resistant recurrent ovarian cancer or patient declines MTOR INHIBITORS AND THEIR CLINICAL APPLICATION IN CERVICAL Review mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: A critical review Nader Husseinzadeha,⁎, Holleh D. Husseinzadehb a Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Cincinnati, 231 Albert Sabin Way Cincinnati, OH 45267-0526, USA b Abramson Cancer Center, Division of Hematology-Oncology, University of PHASE II TRIAL OF ALTERNATING COURSES OF MEGESTROL ACETATE Objectives. To estimate the objective response rate and toxicity associated with alternating megestrol acetate (MA) and tamoxifen citrate (T) in women with endometrial carcinoma.Methods. Consenting patients with measurable recurrent or advanced endometrial carcinoma were eligible if they had not received prior cytotoxic or hormonal treatment. MA 80 mg BID × 3 weeks alternating with T 20 WEEKLY TOPOTECAN FOR RECURRENT ENDOMETRIAL CANCER: A CASE Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature Tiffany A. Traina, Paul Sabbatini, Carol Aghajanian, Jakob Dupont* PHASE II TRIAL OF VINORELBINE FOR RELAPSED OVARIAN CANCER Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study Mace L. Rothenberga,*, P.Y. Liub, Sharon Wilczynskic, William A. Nahhasd ARTICLES IN PRESS: GYNECOLOGIC ONCOLOGY Gynecologic oncology treatment modifications or delays in response to the COVID-19 pandemic in a publicly funded versus privately funded North American tertiary cancer center. Sabrina Piedimonte, Sue Li, Stephane Laframboise, Paulina Cybulska, Michael J. Worley Jr, Taymaa May. Published online: April 28, 2021. HORMONE THERAPY (HT) IN WOMEN WITH GYNECOLOGIC CANCERS AND6AMERICAN SOCIETY OF GYNECOLOGIC ONCOLOGYSOCIETY OF GYNECOLOGIC ONCOLOGYHORMONE THERAPY AFTER BREAST CANCERHORMONE THERAPY FOR CANCER TREATMENTSOCIETY OF GYNECOLOGIC ONCOLOGISTSSOCIETY OF GYNECOLOGIC ONCOLOGY SGO Approximately 40% of women with gynecologic malignancies are pre- or perimenopausal at the time of diagnosis . Combined multimodality therapy including surgery, chemotherapy and/or radiation often results in induced menopause. The Society of Gynecologic Oncology and NCCN recommend prophylactic risk reducing surgery between ages 35–45, or at the completion of child GOG-99: ENDING THE CONTROVERSY REGARDING PELVICGOG 99 CRITERIAGOG 99 KEYSGOG 249GOG CLINICAL TRIALS At last, the results of Gynecological Oncology Group (GOG) trial 99, a randomized trial comparing postoperative pelvic radiotherapy (RT) to no additional treatment (NAT) in intermediate-risk endometrial carcinoma, are published by Keys et al. in this issue of Gynecologic Oncology. Ever since the first presentation of the results in 1998, the gynecologic oncology community has been eagerly LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Late-Breaking Abstracts Scientific Plenary III: Cutting Edge Science Sunday, March 25, 2012 Moderators: Tom Krivak, MD, Magee-WomensHospital of UPMC,
PRELIMINARY SAFETY, EFFICACY, AND PHARMACOKINETIC Objective: TSR-042 is an investigational humanized antiprogrammed death (PD)–1 monoclonal antibody that binds with high affinity to the PD-1 receptor and effectively blocks interaction with the ligands PD-L1 and PD-L2. TSR-042 is being evaluated in patients with advanced solid tumors in the ongoing phase I/II GARNET trial (NCT02715284) (Sachdev JC et al. Ann Oncol. 2017(suppl AN OPEN-LABEL, PHASE II BASKET STUDY OF OLAPARIB AND Objective: Olaparib (Lynparza™) is a poly(ADP-ribose) polymerase inhibitor (PARPi) approved for the treatment and maintenance therapy of ovarian cancer (OC). Here, the objective was to assess the efficacy and safety of olaparib in combination with durvalumab (Imfinzi™), an antiprogrammed cell death ligand-1 (PD-L1) agent, in the platinum-sensitive relapsed (PSR) OC LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Objective: To determine if the combination of carboplatin and paclitaxel (TC) chemotherapy is clinically inferior to the combination of doxorubicin, cisplatin, and paclitaxel (TAP) chemotherapy with regard to survival. To assess differences in toxicity profile, specifically neurotoxicity and infection between TAP and TC. HORMONAL REPLACEMENT THERAPY IN PATIENTS AFTER CERVICALHORMONE THERAPY AFTER BREAST CANCERHORMONE REPLACEMENT AFTER BREAST CANCERHORMONE THERAPY PROSTATE CANCER SURVIVALPOSTMENOPAUSAL HORMONE THERAPY BREASTC…
GYNECOLOGIC ONCOLOGY 26, 169-177 (1987) Hormonal Replacement Therapy in Patients after Cervical Cancer Treatment ELZBIETA PLOCH, M.D. Department of Gynecological Oncology, Maria-Sktodowska Institute ofOncology in Warsaw,
PLATINUM DESENSITIZATION IN PATIENTS WITH CARBOPLATINCISPLATIN DESENSITIZATION PROTOCOLPLATINUM DESENSITIZATIONCARBOPLATIN DESENSITIZATION CALCULATORTAXOL DESENSITIZATIONCARBOPLATIN DESENSITIZATION PACLITAXELPLATINUM BASED CHEMOTHERAPY DESENSITIZAT… Following the CTCAE v. 4.03 we categorized grades 1 and 2 HSRs as mild/moderate and grades 3 and 4 as severe/life-threatening (Table 1). Finally, the number of successfully completed platinum cycles per- ELECTROSURGICAL BIPOLAR VESSEL SEALING FOR RADICAL Electrosurgical bipolar vessel sealing for radical abdominal hysterectomy Karl Tamussinoa,*, Pedram Afschara, Jochen Reussa, Michael Perschlerb, George Ralphb, Raimund Wintera aDepartment of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria bDepartment of Obstetrics and Gynecology, Landeskrankenhaus Leoben, Leoben, Austria Received 22 June 2004 ARTICLES IN PRESS: GYNECOLOGIC ONCOLOGY Gynecologic oncology treatment modifications or delays in response to the COVID-19 pandemic in a publicly funded versus privately funded North American tertiary cancer center. Sabrina Piedimonte, Sue Li, Stephane Laframboise, Paulina Cybulska, Michael J. Worley Jr, Taymaa May. Published online: April 28, 2021. HORMONE THERAPY (HT) IN WOMEN WITH GYNECOLOGIC CANCERS AND6AMERICAN SOCIETY OF GYNECOLOGIC ONCOLOGYSOCIETY OF GYNECOLOGIC ONCOLOGYHORMONE THERAPY AFTER BREAST CANCERHORMONE THERAPY FOR CANCER TREATMENTSOCIETY OF GYNECOLOGIC ONCOLOGISTSSOCIETY OF GYNECOLOGIC ONCOLOGY SGO Approximately 40% of women with gynecologic malignancies are pre- or perimenopausal at the time of diagnosis . Combined multimodality therapy including surgery, chemotherapy and/or radiation often results in induced menopause. The Society of Gynecologic Oncology and NCCN recommend prophylactic risk reducing surgery between ages 35–45, or at the completion of child GOG-99: ENDING THE CONTROVERSY REGARDING PELVICGOG 99 CRITERIAGOG 99 KEYSGOG 249GOG CLINICAL TRIALS At last, the results of Gynecological Oncology Group (GOG) trial 99, a randomized trial comparing postoperative pelvic radiotherapy (RT) to no additional treatment (NAT) in intermediate-risk endometrial carcinoma, are published by Keys et al. in this issue of Gynecologic Oncology. Ever since the first presentation of the results in 1998, the gynecologic oncology community has been eagerly LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Late-Breaking Abstracts Scientific Plenary III: Cutting Edge Science Sunday, March 25, 2012 Moderators: Tom Krivak, MD, Magee-WomensHospital of UPMC,
PRELIMINARY SAFETY, EFFICACY, AND PHARMACOKINETIC Objective: TSR-042 is an investigational humanized antiprogrammed death (PD)–1 monoclonal antibody that binds with high affinity to the PD-1 receptor and effectively blocks interaction with the ligands PD-L1 and PD-L2. TSR-042 is being evaluated in patients with advanced solid tumors in the ongoing phase I/II GARNET trial (NCT02715284) (Sachdev JC et al. Ann Oncol. 2017(suppl AN OPEN-LABEL, PHASE II BASKET STUDY OF OLAPARIB AND Objective: Olaparib (Lynparza™) is a poly(ADP-ribose) polymerase inhibitor (PARPi) approved for the treatment and maintenance therapy of ovarian cancer (OC). Here, the objective was to assess the efficacy and safety of olaparib in combination with durvalumab (Imfinzi™), an antiprogrammed cell death ligand-1 (PD-L1) agent, in the platinum-sensitive relapsed (PSR) OC LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Objective: To determine if the combination of carboplatin and paclitaxel (TC) chemotherapy is clinically inferior to the combination of doxorubicin, cisplatin, and paclitaxel (TAP) chemotherapy with regard to survival. To assess differences in toxicity profile, specifically neurotoxicity and infection between TAP and TC. HORMONAL REPLACEMENT THERAPY IN PATIENTS AFTER CERVICALHORMONE THERAPY AFTER BREAST CANCERHORMONE REPLACEMENT AFTER BREAST CANCERHORMONE THERAPY PROSTATE CANCER SURVIVALPOSTMENOPAUSAL HORMONE THERAPY BREASTC…
GYNECOLOGIC ONCOLOGY 26, 169-177 (1987) Hormonal Replacement Therapy in Patients after Cervical Cancer Treatment ELZBIETA PLOCH, M.D. Department of Gynecological Oncology, Maria-Sktodowska Institute ofOncology in Warsaw,
PLATINUM DESENSITIZATION IN PATIENTS WITH CARBOPLATINCISPLATIN DESENSITIZATION PROTOCOLPLATINUM DESENSITIZATIONCARBOPLATIN DESENSITIZATION CALCULATORTAXOL DESENSITIZATIONCARBOPLATIN DESENSITIZATION PACLITAXELPLATINUM BASED CHEMOTHERAPY DESENSITIZAT… Following the CTCAE v. 4.03 we categorized grades 1 and 2 HSRs as mild/moderate and grades 3 and 4 as severe/life-threatening (Table 1). Finally, the number of successfully completed platinum cycles per- ELECTROSURGICAL BIPOLAR VESSEL SEALING FOR RADICAL Electrosurgical bipolar vessel sealing for radical abdominal hysterectomy Karl Tamussinoa,*, Pedram Afschara, Jochen Reussa, Michael Perschlerb, George Ralphb, Raimund Wintera aDepartment of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria bDepartment of Obstetrics and Gynecology, Landeskrankenhaus Leoben, Leoben, Austria Received 22 June 2004 HOME PAGE: GYNECOLOGIC ONCOLOGY The Society of Gynecologic Oncology (SGO) is the premier medical specialty society for health care professionals trained in the comprehensive management of gynecologic cancers. As a 501(c)(6) organization, the SGO contributes to the advancement of women's cancer care by encouraging research, providing education, raising standards of practice, advocating for patients and members and LIST OF ISSUES: GYNECOLOGIC ONCOLOGY 2021 ( Volume 161) June 2021 Issue 3, p639-914. May 2021 Issue 2, p331-638. April 2021 Issue 1, p1-330. ARTICLES IN PRESS: GYNECOLOGIC ONCOLOGY Gynecologic oncology treatment modifications or delays in response to the COVID-19 pandemic in a publicly funded versus privately funded North American tertiary cancer center. Sabrina Piedimonte, Sue Li, Stephane Laframboise, Paulina Cybulska, Michael J. Worley Jr, Taymaa May. Published online: April 28, 2021. GYNECOLOGIC ONCOLOGY Gynecologic Oncology Podcast on the Future of the Gyn Onc Subspecialty. In this new, Special Edition of the Gynecologic Oncology video podcast, The Future of Gynecologic Oncology: We are at a Crossroads, David E. Cohn, MD, MBA, President of the SGO and Deputy Editor of Gynecologic Oncology, and Warner K. Huh, MD, Immediate Past-President of the 51ST ANNUAL MEETING OF THE SOCIETY The Society of Gynecologic Oncology (SGO) was scheduled to conduct its 2020 Annual Meeting on Women's Cancer®, March 28–31, in Toronto, Canada. Due to the COVID-19 global pandemic, SGO decided not to conduct its annual meeting for the first time in its history. On March 28, SGO released all annual meeting abstracts to the general public, and in April launched a series of free webinars to GYNECOLOGIC ONCOLOGY Historical Perspectives. Invited Reviews. Mechanisms of Disease in Clinical Context. Meeting Reports. NRG Oncology / GOG Studies. SGO Publications. State of ENHANCED RECOVERY AFTER SURGERY (ERAS®) IN GYNECOLOGIC There has been widespread interest in the Enhanced Recovery After Surgery (ERAS®) guidelines in gynecologic oncology as evidenced by these articles being among the most downloaded from the Journal since February 2016 . Despite this, many clinical departments still grapple with how to initiate their ERAS® program, particularly as it relates to translating the guidelines AN OPEN-LABEL, PHASE II BASKET STUDY OF OLAPARIB AND Objective: Olaparib (Lynparza™) is a poly(ADP-ribose) polymerase inhibitor (PARPi) approved for the treatment and maintenance therapy of ovarian cancer (OC). Here, the objective was to assess the efficacy and safety of olaparib in combination with durvalumab (Imfinzi™), an antiprogrammed cell death ligand-1 (PD-L1) agent, in the platinum-sensitive relapsed (PSR) OC LATE-BREAKING ABSTRACT 1: RANDOMIZED PHASE III Objective: To determine if the combination of carboplatin and paclitaxel (TC) chemotherapy is clinically inferior to the combination of doxorubicin, cisplatin, and paclitaxel (TAP) chemotherapy with regard to survival. To assess differences in toxicity profile, specifically neurotoxicity and infection between TAP and TC. A PHASE III TRIAL OF SURGERY WITH OR WITHOUT ADJUNCTIVE The primary outcome, recurrence-free interval (RFI), is defined as the time from study entry to clinical, histologic, or radiographic evidence of disease recurrence. Skip to Main Content__
LOGIN TO YOUR ACCOUNTEmail/Username
PasswordShow
Forgot password?
Remember me
Don’t have an account?Create a Free Account__
If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting yourpassword
Email*
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your passwordCancel
___Close_
* Home
* Articles & Issues__* __Back
* Articles In Press
* Current Issue
* List of Issues
* Supplements
* ABOG__
* __Back
* 2021 MOC Articles
* 2020 MOC Articles
* Collections__
* __Back
* Historical Perspectives* Invited Reviews
* Mechanisms of Disease in Clinical Context* Meeting Reports
* NRG Oncology / GOG Studies* SGO Publications
* State of the Science* Surgical Films
* Tumor Board Papers* For Authors__
* __Back
* About Open Access __ * Author Information* Permissions
* Researcher Academy __ * Submit a Manuscript __* Journal Info__
* __Back
* About the Journal
* About Open Access __ * Abstracting/Indexing * Activate Online Access __ * Career Opportunities __ * Contact Information* Editorial Board
* Info for Advertisers __ * New Content Alerts* Pricing
* Reprints __
* Podcasts
* Subscribe
* SGO__
* __Back
* Member Access
* More Periodicals__* __Back
* Find a Periodical
* Go to Product Catalog* Register
* Subscribe
* Claim
__
Go search
All ContentArticle TitleAuthorsKeywordsAbstractArticle Title,Abstract, Keywords
Advanced Search
Save
search
Please enter a term before submitting your search.Ok__
* Log in
* Register
*
Log in
* Subscribe
* Claim
ISSUE HIGHLIGHTS
*
Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastaticvaginal melanoma
Duygu Sezen, Roshal R. Patel, Christine Tang, Michaela Onstad, Priyadharsini Nagarajan, Sapna P. Patel, James W. Welsh, Lilie L. Lin DOI: https://doi.org/10.1016/j.ygyno.2021.03.017*
Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials Roni Nitecki, Alexander Melamed, Allison A. Gockley, Jessica Floyd, Kate J. Krause, Robert L. Coleman, Ursula A. Matulonis, Sharon H. Giordano, Karen H. Lu, J. Alejandro Rauh-Hain DOI: https://doi.org/10.1016/j.ygyno.2021.03.011*
Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer Roni Nitecki, Nicole D. Fleming, Bryan M. Fellman, Larissa A. Meyer, Anil K. Sood, Karen H. Lu, J. Alejandro Rauh-Hain DOI: https://doi.org/10.1016/j.ygyno.2021.04.012*
ARTICLES IN PRESS
*
Most Cited
*
Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: AMarkov analysis
Sarah A. Ackroyd, Elbert S. Huang, Katherine C. Kurnit, Nita K. Lee DOI: https://doi.org/10.1016/j.ygyno.2021.05.038 Publication stage: In Press Corrected Proof*
Prospective analysis of circulating metabolites and endometrial cancerrisk
Laure Dossus, Eirini Kouloura, Carine Biessy, Vivian Viallon, Alexandros P. Siskos, Niki Dimou, Sabina Rinaldi, Melissa A. Merritt, Naomi Allen, Renee Fortner, Rudolf Kaaks, Elisabete Weiderpass, Inger T. Gram, Joseph A. Rothwell, Lucie Lécuyer, Gianluca Severi, Matthias B. Schulze, Therese Haugdahl Nøst, Marta Crous-Bou, Maria-Jose Sánchez, Pilar Amiano, Sandra M. Colorado-Yohar, Aurelio Barricarte Gurrea, Julie A. Schmidt, Domenico Palli, Claudia Agnoli, Rosario Tumino, Carlotta Sacerdote, Amalia Mattiello, Roel Vermeulen, Alicia K. Heath, Sofia Christakoudi, Konstantinos K. Tsilidis, Ruth C. Travis, Marc J. Gunter, Hector C. Keun DOI: https://doi.org/10.1016/j.ygyno.2021.06.001 Publication stage: In Press Corrected Proof*
Trends and geographic variation in women's representation as principal investigators (PI) in phase 3 gynecologic oncology clinical trials Jessica Jou, Allison Brodsky, Lindsey Charo, Pratibha Binder, Cheryl Saenz, Ramez N. Eskander, Michael McHale, Steve Plaxe DOI: https://doi.org/10.1016/j.ygyno.2021.05.037 Publication stage: In Press Corrected Proof*
Eligibility for cervical cancer screening exit: Comparison of a national and safety net cohort Jacqueline M. Mills, Jake R. Morgan, Amareen Dhaliwal, Rebecca B.Perkins
DOI: https://doi.org/10.1016/j.ygyno.2021.05.035 Publication stage: In Press Corrected Proof*
Risk of venous thromboembolism for ovarian cancer patients during first-line therapy after implementation of an Enhanced Recovery After Surgery (ERAS) protocol Sue Li, Alexandra S. Bercow, Michele Falzone, Rajeshwari Kalyanaraman, Michael J. Worley, Colleen M. Feltmate, Andrea Pelletier, Kevin M.Elias
DOI: https://doi.org/10.1016/j.ygyno.2021.05.032 Publication stage: In Press Corrected Proof View More Articles in Press2020 CITED ARTICLES
ISSN%280090-8258%29+AND+PUBYEAR+IS+2020+ ------------------------- * Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis * Minimally invasive surgery versus laparotomy for radical hysterectomy in the management of early-stage cervical cancer:Survival outcomes
* Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002) * Patient-reported outcomes after surgery for endometrial carcinoma: Prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy * Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification ABOUT _GYNECOLOGIC ONCOLOGY_ _Gynecologic Oncology_, an international journal, is devoted to the publication of clinical and investigative articles that concern tumors of the female reproductive tract. Investigations relating to the etiology, diagnosis, and treatment of female cancers, as well as research from any of the disciplines related to this field of interest, are published.ABOUT SGO
The Society of Gynecologic Oncology (SGO) is the premier medical specialty society for health care professionals trained in the comprehensive management of gynecologic cancers. As a 501(c)(6) organization, the SGO contributes to the advancement of women's cancer care by encouraging research, providing education, raising standards of practice, advocating for patients and members and collaborating with other domestic and international organizations. SGO has more than 2,000 members representing the entire gynecologic oncology team in the United States and abroad. Members include primarily gynecologic oncologists, as well as medical oncologists, pathologists, radiation oncologists, hematologists, surgical oncologists, obstetrician/gynecologists, nurses, physician assistants, social workers, fellows-in-training, residents and other allied health care professionals interested in the treatment and care of women's cancer. SGO members provide multidisciplinary cancer treatment including chemotherapy, radiation therapy, surgery and supportive care. They practice in a variety of settings, including academic institutions and hospitals, major regional cancer centers and privatepractice.
It is the mission of the SGO to promote the highest quality of comprehensive clinical care through education and research in the prevention and treatment of gynecologic cancers.CURRENT ISSUE
* June 2021
* Volume 161, Issue 3June 2021
Volume 161, Issue 3
Access this journal on ScienceDirect Visit ScienceDirect to see if you have access via your institution.New Content Alerts
LIST OF ISSUES
Supports Open Access Learn more about open access options.
Your browser does not support the video tag. GYNECOLOGIC ONCOLOGY PODCAST ON THE FUTURE OF THE GYN ONC SUBSPECIALTY In this new, Special Edition of the Gynecologic Oncology video podcast, The Future of Gynecologic Oncology: We are at a Crossroads, David E. Cohn, MD, MBA, President of the SGO and Deputy Editor of Gynecologic Oncology, and Warner K. Huh, MD, Immediate Past-President of the SGO, engage in a lively discussion about Dr. Huh’s vision for the SGO and gynecologic oncology as a subspecialty. Initially envisioned as part of Dr. Huh’s Presidential Address for the SGO 2020 Annual Meeting in Toronto, this podcast puts the events of the past year in perspective, while remaining focused on the long-term future of gynecologic oncology. IF YOU EXPERIENCE TROUBLE LISTENING TO THE PODCASTS, PLEASE DOWNLOAD THE MP3 FILE, RIGHT-CLICK (ON A PC) OR CONTROL-CLICK (ON A MAC) AND CHOOSE "SAVE LINK AS" TO PLAY ON YOUR COMPUTER.PODCASTS
12345678910
APRIL 2021: DIFFERENCES IN CERVICAL CANCER SCREENING AND FOLLOW-UP FOR BLACK AND WHITE WOMEN IN THE UNITED STATES Twitter Facebook LinkedIn Mendeley Email AddThisHOST: Barbara Goff:
Deputy Editor, Gynecologic Oncology and Gynecologic Oncology Reports FEATURING: Sabrina Ford & Sandra BrooksDownload audio
Subscribe to podcast: RssBrowse all
Gynecologic Oncology audio MARCH 2021: THE FUTURE OF GYNECOLOGIC ONCOLOGY: WE ARE AT A CROSSROADS Twitter Facebook LinkedIn Mendeley Email AddThis HOST: David E. Cohn, MD, MBA, President, Society of GynecologicOncology,
Deputy Editor Gynecologic Oncology GUEST: Warner K. Huh, MD; Immediate Past-President, Society of Gynecologic OncologyDownload audio
Subscribe to podcast: RssBrowse all
Gynecologic Oncology audio APRIL 2020: 2020 RARE TUMORS AND CONDITIONS Twitter Facebook LinkedIn Mendeley Email AddThis Paper: Rare Gynecologic Tumors: Coming of Age HOSTED BY: DR. LAUREL RICE, Associate Editor Featuring: Dr. David Gershenson, Unveristy of TexasDownload audio
Subscribe to podcast: RssBrowse all
Gynecologic Oncology audio AUGUST 2020: 2020 VIRTUAL ANNUAL SGO MEETING REPORT Twitter Facebook LinkedIn Mendeley Email AddThis Paper: The 2020 SGO Annual Meeting Report HOSTED BY: DR. WARNER HUH, Immediate Past President of SGO Featuring: Dr. Kenneth Kim, Scientific Program Co-Chair, 2020 VirtualAnnual SGO Meeting
Dr. Kathleen Moore, Scientific Program Co-Chair, 2020 Virtual AnnualSGO Meeting
Download audio
Subscribe to podcast: RssBrowse all
Gynecologic Oncology audio PARP INHIBITOR MAINTENANCE THERAPY AFTER INITIAL CHEMOTHERAPY FOR ADVANCED OVARY, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCERS Twitter Facebook LinkedIn Mendeley Email AddThis HOSTED BY: DR. DEBORAH K. ARMSTRONG Featuring: Dr. Eskander, Dr. O’Cearbhaill, Dr. Pothuri Continuing education (CE)—0.5 credits—is available through SGOConnectEd
Link:
https://sgo.peachnewmedia.com/store/seminar/seminar.php?seminar=156603 CE description: The Society of Gynecology Oncology designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation on each activity.Download audio
Subscribe to podcast: RssBrowse all
Gynecologic Oncology audio SPECIAL TOPICS: PRESENT AND FUTURE IMPACT OF COVID-19 ON THE PRACTICE AND DELIVERY ON GYNECOLOGIC ONCOLOGY CARE Twitter Facebook LinkedIn Mendeley Email AddThis Basic Advice when dealing with COVID-19 MODERATOR: WARNER K. HUH, MD, 2019-2020 SGO PRESIDENT, UNIVERSITY OF ALABAMA AT BIRMINGHAM Guest: Elizabeth M. Swisher, MD, University of Washington (UW)Medicine, Seattle
Download audio
Subscribe to podcast: RssBrowse all
Gynecologic Oncology audio FEBRUARY 2020 EDITOR'S CHOICE: FINANCIAL HARDSHIP AMONG GYNECOLOGICCANCER PATIENTS
Twitter Facebook LinkedIn Mendeley Email AddThis Editor's Choice Paper: Extensive financial hardship among gynecologic cancer patients starting a new line of therapy Editorial Paper: Financial toxicity: An adverse effect worth of ablack box warning?
HOSTED BY: DR. BETH KARLAN, Editor-In-Chief Featuring: Dr. Karlan, Dr. Liang, Dr. Rauh-HainDownload audio
Subscribe to podcast: RssBrowse all
Gynecologic Oncology audio JANUARY 2020 EDITOR’S CHOICE - _DOES THE TRANSCRIPTOME OF OVARIAN NEOPLASMS PROVIDE INSIGHT INTO ITS POTENTIAL BEHAVIOR?_ Twitter Facebook LinkedIn Mendeley Email AddThis Editor's Choice Paper: Genomic heterogeneity in peritoneal implants: A differential analysis of gene expression using nanostring Human Cancer Reference panel identifies a malignant signature Editorial Paper: Not All Peritoneal Implants Are Created Equal HOSTED BY: DR. DAVID COHN, Deputy Editor Featuring: Dr. Cohn, Dr. Fauceglia, Dr. ShihDownload audio
Subscribe to podcast: RssBrowse all
Gynecologic Oncology audio DECEMBER 2019 EDITOR'S CHOICE Twitter Facebook LinkedIn Mendeley Email AddThis Editor's Choice Paper: A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study Editorial Paper: Sunset, or dawn of a new age for ovarian cancervaccine therapy?
HOSTED BY: DR. BARBARA GOFF, Deputy Editor Featuring: Dr. O'Cearbhaill, Dr. Jazaeri, Dr. GoffDownload audio
Subscribe to podcast: RssBrowse all
Gynecologic Oncology audio NOVEMBER 2019 EDITOR’S CHOICE - _SURVIVAL OF ENDOMETRIAL CANCER PATIENTS FOLLOWING LYMPHADENECTOMY OR SENTINEL NODE PROCEDURE_ Twitter Facebook LinkedIn Mendeley Email AddThis Editor's Choice Paper: Role of lymphadenectomy in endometrial cancer with nonbulky lymph node metastasis: Comparison of comprehensive surgical staging and sentinel lymph node algorithm Editorial Paper: Enough already: Is this the end of comprehensive lymphadenectomy in endometrial cancer or are further trials needed? HOSTED BY: DR. STEPHEN RUBIN, Deputy Editor Featuring: Dr. Rubin, Dr. Mariani, Dr. FaderDownload audio
Subscribe to podcast: RssBrowse all
Gynecologic Oncology audioSURGICAL FILMS
1234
A NOVEL LAPAROSCOPIC TECHNIQUE FOR RETRO-AORTIC AND RETRO-CAVALLYMPHADENECTOMY
*
*
*
Volume 157, Issue 3
Chang Liu, Kristina Duan, Xiaolei Liang, Xiao Lv, Dajiang Liu, YongxiuYang, Xiaoming Guan
Read associated article Browse all Gynecologic Oncology videos METASTATIC PERIPANCREATIC LYMPH NODES RESECTION DURING PRIMARY DEBULKING SURGERY FOR PRIMARY PERITONEAL SEROUS CARCINOMA*
*
*
Volume 157, Issue 2
Kyoko Nishikimi, Shinichi Tate, Ayumu Matsuoka, Nozomu Sakai, MasayukiOtsuka, Makio Shozu
Read associated article Browse all Gynecologic Oncology videos LAPAROSCOPIC SPLENECTOMY FOR SECONDARY CYTOREDUCTION OF OVARIAN CANCER IN A WOMAN WITH LOCALIZED SPLENIC RECURRENCE*
*
*
Volume 156, Issue 3
Stefany Acosta-Torres, Amanda N. Fader Read associated article Browse all Gynecologic Oncology videos SURGICAL TECHNIQUE FOR THE SENTINEL LYMPH NODE (SLN) MAPPING IN 10STEPS
*
*
*
Volume 156, Issue 3
Sara Paracchini, Pauline Chauvet, Krzysztof Gałczyński, Emmanuelle Boulay, Lucie Jaillet, Michel Canis, Nicolas Bourdel Read associated article Browse all Gynecologic Oncology videosJOURNAL METRICS
2019 Impact Factor: 4.623 View More on Journal Insights 2019 Journal Citation Report Clarivate Analytics, 2020 GYNECOLOGIC ONCOLOGY REPORTS Gynecologic Oncology is a Companion Journal to Gynecologic OncologyReports
, which
is a new, online-only, Open Access journal devoted to the rapid publication of case reports. ABSTRACT BOOK FROM THE 51ST ANNUAL MEETING ON WOMEN'S CANCER This supplement contains the abstracts selected for presentation at the 2020 Annual Meeting.Access it here.
JOURNAL ACCESS
Full-text articles are available from 1973 to the present. Access to abstracts is complimentary. Access to full text is limited to Society of Gynecologic Oncology members as well as personal subscribers. Activate Online AccessJOURNAL INSIGHTS
These journal metricsprovide
authors with extra insight into the journals and help them in their journal selection process when submitting an article for publication. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin imperdiet nibh sed ipsum molestie eu mattis justo malesuada. Curabitur id quam augue, ac eleifend justo. Integer eget metus sagittis velit semper auctor vel et nunc. Phasellus tempus felis at arcu fringilla at ndimentum libero placerat. Aenean ut imperdiet dolor. Nulla pretium mi vestibulum dui dictum sed ullamcorper tellus sodales. Duis non nibh id ipsum feugiat imperdiet id fermentum nunc. Maecenas id ultricies felis. Suspendisse lacinia rhoncus vestibulum. Vestibulum molestie vulputate convallis.Fusce et augue erat, nec mollis mi. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin imperdiet nibh sed ipsum molestie eu mattis justo malesuada. Curabitur id quam augue, ac eleifend justo. Integer eget metus sagittis velit semper auctor vel et nunc. Phasellus tempus felis at arcu fringilla at ndimentum libero placerat. Aenean ut imperdiet dolor. Nulla pretium mi vestibulum dui dictum sed ullamcorper tellus sodales. Duis non nibh id ipsum feugiat imperdiet id fermentum nunc. Maecenas id ultricies felis. Suspendisse lacinia rhoncus vestibulum. Vestibulum molestie vulputate convallis.Fusce et augue erat, nec mollis mi.* Home
* Articles & Issues
* Articles In Press
* Current Issue
* List of Issues
* Supplements
* ABOG
* 2021 MOC Articles
* 2020 MOC Articles
* Collections
* Historical Perspectives* Invited Reviews
* Mechanisms of Disease in Clinical Context* Meeting Reports
* NRG Oncology / GOG Studies* SGO Publications
* State of the Science* Surgical Films
* Tumor Board Papers* For Authors
* About Open Access
* Author Information* Permissions
* Researcher Academy * Submit a Manuscript* Journal Info
* About the Journal
* About Open Access
* Abstracting/Indexing * Activate Online Access * Career Opportunities * Contact Information* Editorial Board
* Info for Advertisers * New Content Alerts* Pricing
* Reprints
* Podcasts
* Subscribe
* SGO
* Member Access
* More Periodicals
* Find a Periodical
* Go to Product Catalog* Follow Us
professionals.
* Privacy Policy
* Terms and Conditions* Accessibility
* Help & Contact
Click to get updates and verify authenticity. Submit your next paper to Gynecologic Oncology We use cookies to analyse and improve our service, to improve and personalise content, advertising and your digital experience. We also share information about your use of our site with our social media, advertising and analytics partners. Cookie Policy Cookie Settings Accept all cookiesDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0